Results 91 to 100 of about 38,738 (212)

Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues

Molecular Metabolism
Objectives: Unimolecular triagonists drive substantial weight loss in patients with obesity by engaging the glucagon-like peptide 1 receptor (GLP-1R) and glucose dependent insulinotropic polypeptide receptor (GIPR) to reduce food intake (FI) and the ...
Jonathan D. Douros, Megan Capozzi, Aaron Novikoff, Jacek Mokrosinski, Barent DuBois, Joseph Stock, Rebecca Rohlfs, Mikayla Anderson, Dominika J. Jedrzejcyk, Svend Poulsen, Erik Oude Blenke, Tomas Dago, Kasper Huus, Peder L. Nørby, Sune Kobberup, Marita Rivir, Joyce Sorrell, Stephanie A. Mowery, Daniel J. Drucker, David A. D'Alessio, Jonathan E. Campbell, Timo D. Müller, Diego Perez-Tilve, Brian Finan, Patrick J. Knerr   +24 more
doaj   +1 more source

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting

Endocrinology, Diabetes & Metabolism
Objective Incidence of type 2 diabetes mellitus (T2DM) and obesity is increasing in children. We aimed to observe the metabolic health effects of glucagon‐like peptide 1 (GLP‐1) receptor agonists in paediatric patients with T2DM in a real‐world setting ...
A. G. Barajas, Charles A. Gagnon‐Vargas, Jessica A. Schmitt   +2 more
doaj   +1 more source

Targeting GLP-1 receptor trafficking to improve agonist efficacy

Nature Communications, 2018
Glucagon-like peptide-1 receptor (GLP-1R) promotes insulin secretion from pancreatic beta cells and undergoes agonist-mediated endocytosis. Here, authors study GLP-1R endocytosis caused by different agonists and show that a longer plasma membrane ...
Ben Jones, Teresa Buenaventura, Nisha Kanda, Pauline Chabosseau, Bryn M. Owen, Rebecca Scott, Robert Goldin, Napat Angkathunyakul, Ivan R. Corrêa Jr, Domenico Bosco, Paul R. Johnson, Lorenzo Piemonti, Piero Marchetti, A. M. James Shapiro, Blake J. Cochran, Aylin C. Hanyaloglu, Asuka Inoue, Tricia Tan, Guy A. Rutter, Alejandra Tomas, Stephen R. Bloom   +20 more
doaj   +1 more source

Experimental colonization with H. hepaticus, S. aureus and R. pneumotropicus does not influence the metabolic response to high-fat diet or incretin-analogues in wildtype SOPF mice

Molecular Metabolism
Objectives: We here assessed whether typical pathogens of laboratory mice affect the development of diet-induced obesity and glucose intolerance, and whether colonization affects the efficacy of the GLP-1R agonist liraglutide and of the GLP-1/GIP co ...
Margit Wunderlich, Manuel Miller, Bärbel Ritter, Ronan Le Gleut, Hannah Marchi, Monir Majzoub-Altweck, Patrick J. Knerr, Jonathan D. Douros, Timo D. Müller, Markus Brielmeier   +9 more
doaj   +1 more source

Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice

Journal of Diabetes Research, 2018
A recent report suggested that brain-derived serotonin (5-HT) is critical for maintaining weight loss induced by glucagon-like peptide-1 (GLP-1) receptor activation in rats and that 5-HT2A receptors mediate the feeding suppression and weight loss induced
Katsunori Nonogaki, Takao Kaji
doaj   +1 more source

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli

Diabetes, Metabolic Syndrome and Obesity
Carol Cheney,1 Krystal Hunter,1 Marlena Klein2 1Cooper Medical School of Rowan University, Camden, NJ, USA; 2Internal Medicine Department, Cooper University Hospital, Camden, NJ, USACorrespondence: Carol Cheney, Cooper Medical School of Rowan University,
Cheney C, Hunter K, Klein M
doaj  

Design, Structure–Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists

Molecules
A systematic structure–activity and computational modeling analysis of a series of glucagon-like peptide-1 receptor (GLP-1R) agonists based upon an ultra-short GLP-1 peptide, H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Bip-Bip-NH2, was conducted.
Jonathon R. Sawyer, Joseph A. Audie, Jon Swanson, David Diller, Solimar Santiago, Valentin K. Gribkoff, Allison Ackerman, Victor J. Hruby, Gianpaolo Gobbo, Michael A. Bellucci, William A. Glauser, Brad L. Pentelute, Tomi K. Sawyer   +12 more
doaj   +1 more source

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

Frontiers in Pharmacology
BackgroundObesity is a chronic inflammatory disease with high morbidity that is decidedly prevalent worldwide and in Saudi Arabia. Glucagon-like peptide 1 receptor agonists (GLP-1 agonists) are broadly used for the management of diabetes and obesity.
Amirah Alhowiti, Hyder Mirghani, Abdulaziz Abdulrahman Qrmli, Amal Abdullah Albalawi, Raneem Abdulrahman Aljohani   +4 more
doaj   +1 more source

Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs

Obesity Pillars
Background: Obesity and type 2 diabetes mellitus (T2DM) are increasingly common in the United States and worldwide. Because both conditions are associated with serious health consequences, weight reduction is recommended by professional medical and ...
Sandra Christensen, Katie Robinson, Sara Thomas, Dominique R. Williams   +3 more
doaj   +1 more source

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal [PDF]

, 2011
This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National ...
Cummins, E. (Ewen), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +3 more
core